Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New eye lens could let cataract patients ditch glasses

NCT ID NCT07607860

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study tests a new type of artificial lens for cataract surgery that may adjust focus like a natural lens. About 100 adults needing cataract surgery will get this lens in one eye and a standard lens in the other. Researchers will check for complications and measure vision improvement over three years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
accommodating intraocular lens (device)
What this could lead to
If successful, this lens could help cataract patients see clearly at multiple distances without glasses.
What could go wrong
This is an early feasibility study with only 100 participants. The lens may not improve vision as hoped, and there are risks like swelling or lens dislocation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults who are at least 21 years of age or older. * Scheduled to undergo primary intraocular lens implantation for the correction of aphakia following phacoemulsification extraction of a senile cataract. * Clear intraocular media other than cataract. * Potential visual acuity of 20/32 or better in both eyes after cataract removal and IOL implantation as determined by diagnostic testing or investigator's judgement. * Preoperative corrected distance visual acuity (CDVA) worse than 20/40 either with or without a glare source present (e.g., Brightness Acuity Tester) or scheduled for cataract removal due to significant cataract-related symptoms/complaints. * Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism. * In good general health at screening as determined by the investigator. * Signed written informed consent. * Availability, willingness, and sufficient cognitive awareness to comply with examination procedures and schedule. Exclusion Criteria: * Planned secondary procedures (such as LASIK) during the term of the study; Nd YAG capsulotomy is permitted. * Taking systemic medications that may confound the outcome or increase the risk to the subject. * Ocular conditions that may predispose for future complications. * Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject. * Pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes. * Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future CDVA loss worse than 20/40. * Any anterior segment pathology (anterior segment or corneal abnormalities, chronic uveitis, iritis, corneal dystrophy, pseudoexfoliation, etc.). * Glaucoma, glaucoma suspect or ocular hypertension, i.e., IOP \> 22 mmHg. * Previous retinal detachment or retinal pathology, including age-related macular degeneration. * Diabetes, currently being treated systemically and with retinopathy. * Systemic or ocular disease that may prevent the patient from achieving CDVA of 20/32 or better post operatively. * Require chronic administration of any topical ophthalmic or systemic medication that may affect accommodation such as mydriatic, cycloplegic and myotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, anticholinergic agents. * CDVA of 20/32 or worse in the fellow eye not attributable to cataract. * Current participation in, or have participated in, an investigational study, other than this study, within the previous 60 days before the operative day. * Previous ocular surgery in the operative eye, including refractive surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aphakia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.